enzamet: enzalutamide for metastatic prostate cancer
Published 5 years ago • 6.4K plays • Length 5:16Download video MP4
Download video MP3
Similar videos
-
1:55
arches trial overview: adt plus enzalutamide for metastatic hormone-sensitive prostate cancer
-
6:40
updated overall survival outcomes in enzamet (anzup 1304)
-
0:42
enzalutamide in the non-metastatic setting for crpc
-
0:47
systemic triple therapy in metastatic hormone-sensitive prostate cancer
-
2:13
head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic crpc
-
0:53
embark: subset analysis of enzalutamide versus leuprolide in prostate cancer
-
2:10
current standards for first-line metastatic hormone-sensitive prostate cancer
-
6:26
enzamet & arches trials provides evidence of enzalutamide as life prolonging therapy in mhspc
-
6:05
enzamet trial
-
5:11
enzalutamide adt in men with de novo mhspc: the arches trial
-
1:17
treatment landscape for metastatic hormone-sensitive prostate cancer
-
3:44
the evolving standard of care for patients with metastatic hormone-sensitive prostate cancer
-
2:46
dr. sweeney on the phase iii enzamet trial in metastatic hormone-sensitive prostate cancer
-
3:19
live long and prosper: enzalutamide for nmcrpc
-
1:34
dr. chi on abiraterone versus enzalutamide for metastatic castration-resistant prostate cancer
-
3:44
updates from the cheiron study: docetaxel plus enzalutamide for mcrpc
-
0:48
future research on srt plus enzalutamide for psa recurrent high-risk prostate cancer
-
1:35
arches: os by high or low disease volume and progression to mhspc or de novo mhspc
-
2:46
first-line treatments in metastatic prostate cancer